IN8BIO, Inc. - ESG Rating & Company Profile powered by AI
Alternative corporations in the rating industry group for IN8BIO, Inc. are displayed. The page contains a zero-cost Environmental, Social and Governance assessment covering IN8BIO, Inc.. The report of IN8BIO, Inc. was assembled by All Street Sevva using proprietary artificial intelligence.
IN8BIO, Inc. in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 5.2; made up of an environmental score of 6.0, social score of 4.0 and governance score of 5.7.
5.2
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Novartis AG | 9.2 | High |
| 2 | Daiichi Sankyo Co Ltd | 8.9 | High |
| 912 | Vivanza Biosciences Ltd | 5.3 | High |
| 912 | ValiRx PLC | 5.3 | High |
| 958 | IN8BIO, Inc. | 5.2 | High |
| 958 | Altimmune Inc | 5.2 | High |
| 958 | Agios Pharmaceuticals Inc | 5.2 | High |
| ... | ... | ... | |
| 2749 | Xynomic Pharmaceuticals Holdings Inc | 0.0 | Low |
| 2749 | Zyden Gentec Ltd | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does IN8BIO, Inc. have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes IN8BIO, Inc. disclose current and historical energy intensity?
Sign up for free to unlockDoes IN8BIO, Inc. report the average age of the workforce?
Sign up for free to unlockDoes IN8BIO, Inc. reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes IN8BIO, Inc. disclose its ethnicity pay gap?
Sign up for free to unlockDoes IN8BIO, Inc. disclose cybersecurity risks?
Sign up for free to unlockDoes IN8BIO, Inc. offer flexible work?
Sign up for free to unlockDoes IN8BIO, Inc. have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes IN8BIO, Inc. disclose the number of employees in R&D functions?
Sign up for free to unlockDoes IN8BIO, Inc. conduct supply chain audits?
Sign up for free to unlockDoes IN8BIO, Inc. disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes IN8BIO, Inc. conduct 360 degree staff reviews?
Sign up for free to unlockDoes IN8BIO, Inc. disclose the individual responsible for D&I?
Sign up for free to unlockDoes IN8BIO, Inc. disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes IN8BIO, Inc. disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes IN8BIO, Inc. disclose water use targets?
Sign up for free to unlockDoes IN8BIO, Inc. have careers partnerships with academic institutions?
Sign up for free to unlockDid IN8BIO, Inc. have a product recall in the last two years?
Sign up for free to unlockDoes IN8BIO, Inc. disclose incidents of discrimination?
Sign up for free to unlockDoes IN8BIO, Inc. allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas IN8BIO, Inc. issued a profit warning in the past 24 months?
Sign up for free to unlockDoes IN8BIO, Inc. disclose parental leave metrics?
Sign up for free to unlockDoes IN8BIO, Inc. disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes IN8BIO, Inc. disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes IN8BIO, Inc. disclose the pay ratio of women to men?
Sign up for free to unlockDoes IN8BIO, Inc. support suppliers with sustainability related research and development?
Sign up for free to unlockDoes IN8BIO, Inc. disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes IN8BIO, Inc. reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs IN8BIO, Inc. involved in embryonic stem cell research?
Sign up for free to unlockDoes IN8BIO, Inc. disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes IN8BIO, Inc. disclose its waste policy?
Sign up for free to unlockDoes IN8BIO, Inc. report according to TCFD requirements?
Sign up for free to unlockDoes IN8BIO, Inc. disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes IN8BIO, Inc. disclose energy use targets?
Sign up for free to unlockDoes IN8BIO, Inc. disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes IN8BIO, Inc. have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for IN8BIO, Inc.
These potential risks are based on the size, segment and geographies of the company.
IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation. It also develops INB-400 and INB-300 that is in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.